In: Sin categoría

Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein
21/09/2022

Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours   LONDON and SANTIAGO DE COMPOSTELA, Spain,…

Read More
Axencia Galega de Innovación